UBS Group AG increased its holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 17.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 107,964 shares of the biotechnology company’s stock after purchasing an additional 16,150 shares during the period. UBS Group AG owned 0.16% of Sarepta Therapeutics worth $7,999,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Zeke Capital Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at $241,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at $261,000. Symphony Asset Management LLC acquired a new position in Sarepta Therapeutics in the first quarter valued at $266,000. Arrowstreet Capital Limited Partnership acquired a new position in Sarepta Therapeutics in the fourth quarter valued at $217,000. Finally, Aperio Group LLC acquired a new position in Sarepta Therapeutics in the fourth quarter valued at $219,000. 86.27% of the stock is owned by institutional investors and hedge funds.
Shares of Sarepta Therapeutics opened at $132.18 on Friday, according to Marketbeat. The stock has a market cap of $8.76 billion, a price-to-earnings ratio of -80.60 and a beta of 1.35. Sarepta Therapeutics Inc has a 12 month low of $32.80 and a 12 month high of $176.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.28 and a current ratio of 13.37.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.23). The company had revenue of $64.60 million for the quarter, compared to analyst estimates of $65.31 million. Sarepta Therapeutics had a negative return on equity of 24.68% and a negative net margin of 83.88%. The company’s revenue for the quarter was up 295.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.57) EPS. equities research analysts predict that Sarepta Therapeutics Inc will post -1.98 earnings per share for the current fiscal year.
In related news, Director Richard Barry sold 75,000 shares of the business’s stock in a transaction dated Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total value of $9,775,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 7.90% of the company’s stock.
A number of research analysts recently weighed in on SRPT shares. Zacks Investment Research cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 22nd. Barclays upgraded Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $55.00 to $107.00 in a report on Friday, May 11th. ValuEngine upgraded Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Morgan Stanley lifted their target price on Sarepta Therapeutics from $63.00 to $64.00 and gave the company an “overweight” rating in a report on Tuesday, March 6th. Finally, William Blair reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. Sarepta Therapeutics has an average rating of “Buy” and a consensus price target of $126.50.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.